PD Dr. Frank Essmann

Group leader at the Dr. Margarete Fischer-Bosch – Institute of Clinical Pharmacology

PD Dr. Frank Essmann

Tel +49-711-8101 5755

frank.essmann@ikp-stuttgart.de

Major Projects

tumor biology / signal transduction
apoptosis / Bcl-2 protein family / mitochondria
senescence / epigenetics
immunology

Selected References

Stehle D, Grimm M, Einsele-Scholz S, Ladwig F, Johänning J, Fischer G, Gillissen B, Schulze-Osthoff K, Essmann F (2018). Contribution of BH3-domain and Transmembrane-domain to the Activity and Interaction of the Pore-forming Bcl-2 Proteins Bok, Bak, and Bax. Sci Rep 8(1):12434

Dannenmann B, Lehle S, Lorscheid S, Huber S, Essmann F, Schulze-Osthoff K (2017). Simultaneous quantification of DNA-damage and mitochondrial copy number by Long-run DNA-damage quantification (LORD-Q). Oncotarget 8(68):112417-25

Gillissen B, Richter A, Richter A, Preissner R, Schulze-Osthoff K, Essmann F, Daniel PT (2017). Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma. J Biol Chem 292(16):6478-92)

Hörber S, Hildebrand DG, Lieb WS, Lorscheid S, Schulze-Osthoff K, Essmann F (2016). The atypical inhibitor of NF-κB, IκBζ, controls macrophage interleukin-10 expression. J Biol Chem 291(24):12851-61

Einsele-Scholz S, Malmsheimer S, Bertram K, Stehle D, Johänning J, Manz M, Gillissen B, Schulze-Osthoff K, Essmann F (2016). Bok is a genuine multi-BH-domain protein that triggers apoptosis in the absence of Bax and Bak and augments drug response. J Cell Sci 129(11):2213-23

Dose A, Sindlinger J, Bierlmeier J, Bakirbas A, Schulze-Osthoff K, Einsele-Scholz S, Hartl M, Essmann F, Finkemeier I, Schwarzer D. (2016). Interrogating Substrate Selectivity and Composition of Endogenous Histone Deacetylase Complexes with Chemical Probes. Angew Chem Int Ed Engl 55(3):1192-5

Dannenmann B, Lehle S, Essmann F, Schulze-Osthoff K (2015). Genome surveillance in pluripotent stem cells: Low apoptosis threshold and efficient antioxidant defense. Mol Cell Oncol 3(2):e1052183

Dannenmann B, Lehle S, Hildebrand DG, Kübler A, Grondona P, Schmid V, Holzer K, Fröschl M, Essmann F, Rothfuss O, Schulze-Osthoff K (2015). High glutathione and glutathione peroxidase-2 levels mediate cell type-specific damage protection in human induced pluripotent stem cells. Stem Cell Reports 4(5):886-98)

Zhang Y, Mu J, Essmann F, Feng Y, Kramer M, Bao HY, Grond S (2015). A new quinolinone and its natural/artificial derivatives from a shark gill-derived fungus Penicillium crustosum AP2T1. Nat Prod Res (17):1-5

Feil S, Fehrenbacher B, Lukowski R, Essmann F, Schulze-Osthoff K, Schaller M, Feil R (2014). Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ Res 115(7):662-7

Lehle S, Hildebrand DG, Merz B, Malak PN, Becker MS, Schmezer P, Essmann F, Schulze-Osthoff K, Rothfuss O (2014). LORD-Q: a long-run real-time PCR-based DNA-damage quantification method for nuclear and mitochondrial genome analysis. Nuceic Acids Res 42(6):e41

Garbers C, Kuck F, Aparicio-Siegmund S, Konzak K, Kessenbrock M, Sommerfeld A, Häussinger D, Lang PA, Brenner D, Mak TW, Rose-John S, Essmann F, Schulze-Osthoff K, Piekorz RP, Scheller J (2013). Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR). Cell Cycle 12(21):3421-32

Dietrich D, Seiler F, Essmann F, Dodt G (2013). Identification of the kinesin KifC3 as a new player for positioning of peroxisomes and other organelles in mammalian cells. Biochim Biophys Acta 1833(12):3013-24

Venturelli S, Berger A, Weiland T, Essmann F, Waibel M, Nuebling T, Häcker S, Schenk M, Schulze-Osthoff K, Salih HR, Fulda S, Sipos B, Johnstone RW, Lauer UM, Bitzer M (2013).Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2'-Deoxycytidine in Solid Tumor Cells. Mol Cancer Ther 12(10):2226-36

Bareiss PM, Paczulla A, Wang H, Schairer R, Wiehr S, Kohlhofer U, Rothfuss OC, Fischer A, Perner S, Staebler A, Wallwiener D, Fend F, Fehm T, Pichler B, Kanz L, Quintanilla-Martinez L, Schulze-Osthoff K, Essmann F, Lengerke C (2013).SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res 73(17):5544-55

Weiland T, Lampe J, Essmann F, Venturelli S, Berger A, Bossow S, Berchthold S, Schulze- Osthoff K, Lauer UM, Bitzer M (2014). Enhanced killing of therapy-induced senescent tumor cells by oncolytic Measles vaccine viruses. Int J Cancer 134(1):235-43

Alexander E, Hildebrand DG, Obermayer K, Manz M, Rothfuss O, Schulze-Osthoff K, Essmann F (2013). IκBζ is a regulator of the senescence-associated secretory phenotype in DNA damage- and oncogene-induced senescence. J Cell Sci 126(Pt 16):3738-45

Hildebrand DG, Lehle S, Borst A, Haferkamp S, Essmann F, Schulze-Osthoff K (2013). A-Fucosidase as a novel convenient biomarker for cellular senescence. Cell Cycle 12(12):1922-7)

Gillissen B, Richter A, Richter A, Overkamp T, Essmann F, Hemmati PG, Preissner R, Belka C, Daniel PT (2013).Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I’ mode. Cell Death Dis 4:e643)

Hildebrand DG, Alexander E, Hörber S, Lehle S, Obermayer K, Münck NA, Rothfuss O, Frick JS, Morimatsu M, Schmitz I, Roth J, Ehrchen JM, Essmann F, Schulze-Osthoff K (2013).IB is a Transcriptional Key Regulator of CCL2/MCP-1. J Immunol 190(9):4812-20

Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, Berdel J, Niessner H, Meier F, van den Broek M, Häring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, Zender L, Schaller M, Schulze-Osthoff K, Röcken M (2013).T-helper-1-cell cytokines drive cancer into senescence. Nature 494(7437):361-5

Trivigno D, Essmann F, Huber SM, Rudner J (2012).Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia 14(10):893-904

Keil E, Höcker R, Schuster M, Essmann F, Ueffing N, Hoffman B, Liebermann DA, Pfeffer K, Schulze-Osthoff K, Schmitz I (2012).Phosphorylation of Atg5 by the Gadd45β-MEKK4-p38 pathway inhibits autophagy. Cell Death Differ 20(2):321-32

Konantz M, André MC, Ebinger M, Grauer M, Wang H, Grzywna S, Rothfuss OC, Lehle S, Kustikova OS, Salih HR, Handgretinger R, Fend F, Baum C, Kanz L, Quintanilla-Martinez L, Schulze-Osthoff K, Essmann F, Lengerke C (2012). EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia. Leukemia 27(1):56-65

Weiland T, Berger A, Essmann F, Lauer U, Bitzer M, Venturelli S (2012). Kinetic tracking of therapy induced senescence using the Real-Time Cell Analyzer SP system. ASSAY and Drug Development Technologies 10(3):289-95

Curriculum Vitae

Professional Education and Career

Since 10/2018

Group leader at the Dr. Margarete Fischer-Bosch – Institute of Clinical Pharmacology, Stuttgart, Germany

2008-2018

Group leader at the Dept of Molecular Medicine (Prof. K. Schulze-Osthoff) / Eberhard-Karls-University Tübingen, Germany

2008

Habilitation in Molecular Medicine at the Heinrich Heine University Düsseldorf. „Regulationsebenen der Apoptose: Vom DNA-Schaden zur Proteinspaltung.“

2002-2008

Junior group leader at the Institute for Molecular Medicine / Heinrich Heine University Düsseldorf (Prof. K. Schulze-Osthoff)

2001-2002

Startup Co-Founder at Proteome Factory AG

1999-2001

Post-doctoral scientist at the Charité / Humboldt University Berlin

1997-1999

PhD thesis: “Mechanisms of Apoptosis in Cancer: Regulatory Role of Caspases” at the Charité / Humboldt University Berlin (Prof. P.T. Daniel) and Max-Delbrück-Centrum (MDC) (Prof. B. Wittmann-Liebold)

1997

Diploma thesis at the Max-Planck-Institute for Molecular Physiology and Diploma in chemistry

1992-1997

Studies in chemistry at the University of Dortmund, Germany